Targeted therapy of common forms of skin melanoma (literature review)
DOI: 10.32364/2587-6821-2024-8-6-5
L.V. Bolotina
P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre, Moscow, Russian Federation
Skin melanoma (SM) refers to malignant skin tumors, originates from melanocytes, has an extremely aggressive course with the spread of hematogenous and lymphogenic metastases. In addition to immunotherapy regimens, targeted drugs can be successfully used to treat patients with SM and BRAF mutations, detected in about half of the cases. In recent years, the arsenal of targeted therapy has expanded due to the introduction into clinical practice of the third combination of BRAF and MEK inhibitors — encorafenib and binimetinib. Given the availability of several combined targeted therapy modes in the oncologist's armamentarium, a logical question arises: is there any reason to consider that one of the combinations takes precedence over the other? How significant are the differences in the toxicity spectrum? On what basis should the oncologist choose a specific regimen in clinical practice? The article presents data on the efficacy and safety of existing targeted combinations obtained in phase III studies, as well as the results of recent published meta-analyses. The treatment regimens are characterized in terms of response level, frequency and nature of adverse events.
Keywords: skin melanoma, BRAF inhibitors, MEK inhibitors, encorafenib, binimetinib, monotherapy, combination therapy.
For citation: Bolotina L.V. Targeted therapy of common forms of skin melanoma (literature review). Russian Medical Inquiry. 2024;8(6):343–349 (in Russ.). DOI: 10.32364/2587-6821-2024-8-6-5.
About the author:
Larisa V. Bolotina — Dr. Sc. (Med.), Head of the Department of Chemotherapy, P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre; 3, 2nd Botkinsky Ave., Moscow, 125284, Russian Federation; ORCID iD 0000-0003-4879-2687.
Contact information: Larisa V. Bolotina, e-mail: lbolotina@yandex.ru.
Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 03.06.2024.
Revised 27.06.2024.
Accepted 22.07.2024.
2. Демидов Л.В., Алиев М.Д., Мартынова Е.В. и др. Прогностические факторы в оценке первичной меланомы кожи и их значение для выбора объема оперативного вмешательства. Материалы VIII Российского онкологического конгресса. (Электронный ресурс.) URL: https://rosoncoweb.ru/library/congress/ru/08/14.php (дата обращения: 18.07.2024).Demidov L.V., Aliev M.D., Martynova E.V. et al. Prognostic factors in the assessment of primary skin melanoma and their importance for choosing the extent of surgical intervention. Proceedings of the VIII Russian Oncology Congress. (Electronic resource.) URL: https://rosoncoweb.ru/library/congress/ru/08/14.php (access date: 18.07.2024) (in Russ.).
3. Sosman J.A., Kim K.B., Schuchter L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714. DOI: 10.1056/NEJMoa1112302.
4. Blank C.U., Larkin J., Arance A.M. et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. Eur J Cancer. 2017;79:176–184. DOI: 10.1016/j.ejca.2017.04.007.
5. Chapman P.B., Robert C., Larkin J. et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(1):2581–2587. DOI: 10.1093/annonc/mdx339.
6. Hauschild A., Grob J.J., Demidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365. DOI: 10.1016/S0140-6736(12)60868-X.
7. Ascierto P.A., Minor D., Ribas A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–3211. DOI: 10.1200/JCO.2013.49.8691.
8. Delord J.P., Robert C., Nyakas M. et al. Phase I Dose-Escalation and — Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in metastatic BRAF-Mutant Melanoma. Clin Cancer Res. 2017;23(18):5339–5348. DOI: 10.1158/1078-0432.CCR-16-2923.
9. Flaherty K.T., Robert C., Hersey P. et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114. DOI: 10.1056/NEJMoa1203421.
10. Kim K.B., Kefford R., Pavlick A.C. et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482–489. DOI: 10.1200/JCO.2012.43.5966.
11. Dummer R., Schadendorf D., Ascierto P.A. et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435–445. DOI: 10.1016/S1470-2045(17)30180-8.
12. Larkin J., Ascierto P.A., Dreno B. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876. DOI: 10.1056/NEJMoa1408868.
13. Long G.V., Stroyakovskiy D., Gogas H. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. DOI: 10.1016/S0140-6736(15)60898-4.
14. Robert C., Karaszewska B., Schachter J. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39. DOI: 10.1056/NEJMoa1412690.
15. Long G.V., Flaherty K.T., Stroyakovskiy D. et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639. DOI: 10.1093/annonc/mdx176. Erratum in: Ann Oncol. 2019;30(11):1848. DOI: 10.1093/annonc/mdz221.
16. Dummer R., Ascierto P.A., Gogas H.J. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFmutant melanoma (COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2018;19:603–615. DOI: 10.1016/S1470-2045(18)30142-6.
17. Dummer R., Ascierto P.A., Gogas H.J. et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, openlabel, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–1327. DOI: 10.1016/S1470-2045(18)30497-2.
18. Burlingham B.T., Widlanski T.S. An intuitive look at the relationship of K1 and IC50: a more general use for the Dixon plot. J Chem Educ. 2003;80(2):214–218. DOI: 10.1021/ed080p214.
19. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5(9):730–739. DOI: 10.1038/nrd2082.
20. Vauquelin G., Charlton S.J. Long-lasting binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol. 2010;161(3):488–508. DOI: 10.1111/j.1476-5381.2010.00936.x.
21. Smith D.A., Beaumont K., Maurer T.S., Di L. Relevance of half-life in drug design. J Med Chem. 2018;61(10):4273–4282. DOI: 10.1021/acs.jmedchem.7b00969.
22. Heinzerling L., Eigentler T.K., Fluck M. et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and anagement. ESMO Open. 2019;4(3):e00491. DOI: 10.1136/esmoopen-2019-000491.
23. Trojaniello C., Festino L., Vanella V., Ascierto P.A. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Rev Clin Pharmacol. 2019;12(3):259–266. DOI: 10.1080/17512433.2019.1570847.
24. Dummer R., Flaherty K.T., Robert C. et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022;40(36):4178–4188. DOI: 10.1200/JCO.21.02659.
25. Robert C., Grob J.J., Stroyakovskiy D. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. DOI: 10.1056/NEJMoa1904059.
26. Gogas H., Dummer R., Ascierto P.A. et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer. 2021;152:116–128. DOI: 10.1016/j.ejca.2021.04.028.
27. Schadendorf D., Dummer R., Flaherty K.T. et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer. 2024;204:114073. DOI: 10.1016/j.ejca.2024.114073.
28. Ascierto P.A., Dréno B., Larkin J. et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021;27(19):5225–5235. DOI: 10.1158/1078-0432.CCR-21-0809.
29. Garutti M., Bergnach M., Polesel J. et al. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers (Basel). 2023;15(1):141. DOI: 10.3390/cancers15010141.
30. Corrie P., Meyer N., Berardi R. et al. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treat Rev. 2022;110:102463. DOI: 10.1016/j.ctrv.2022.102463.
31. Ascierto P.A., Casula M., Bulgarelli J. et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15(1):146. DOI: 10.1038/s41467-023-44475-6.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
